Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 2/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439662 | 0.94 | EED (0.64) | EEDMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10534315 | 0.87 | CETP (0.48) | EEDCETPBACE1ACHEAKR1C3 | |
| SCHEMBL10534361 | 0.84 | EED (0.50) | EEDCETPBACE1AKR1C3 | |
| SCHEMBL793407 | 0.82 | CYP11B2 (0.56) | EEDBACE1CYP11B1CYP11B2 | |
| SCHEMBL10534781 | 0.80 | CETP (0.48) | EEDCETPBACE1ACHEAKR1C3 | |
| SCHEMBL29586558 | 0.79 | EED (0.42) | EED | |
| SCHEMBL21326135 | 0.79 | EED (0.42) | EED | |
| SCHEMBL6441852 | 0.78 | EED (1.00) | EED | |
| SCHEMBL10537614 | 0.78 | ADRB1 (0.46) | CETPBACE1ACHE | |
| SCHEMBL25589686 | 0.78 | EED (0.59) | EEDCHKACYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448547-B1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2005-04-20 | — | — | EP | disclosed |
| US-6831087-B2 | 2-(Pyrid-2- or 4-yl)-1,2,3,4-tetrahydroisoquinoline and derivatives; a good affinity to the NMDA receptor (N-methyl-D-asparate); acute/cronic neurodegenerative diseases; bacterial/viral infections; antidepressants; analgesics | HOFFMANN-LA ROCHE INC. | 2004-12-14 | — | — | US | disclosed |
| EP-1448547-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-20030119870-A1 | Pyridine substituted isoquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | US | disclosed |
| WO-2003040128-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119870-A1 | Pyridine substituted isoquinoline derivatives | GRIN1, GRIN2C, GRIN2A | EED 2041/4885MAPK13 3302/4885MAPK12 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.